Summary
Retrophin Inc. (Retrophin) is a biopharmaceutical company that discovers, acquires, develops and commercializes drugs for the treatment of rare and life threatening diseases. The company develops treatments for pantothenate kinase associated neuro degeneration, focal duchenne muscular dystrophy, segmental glomerulo sclerosis and other catastrophic diseases. It offers products such as thiola, chenodal and cholbam. Retrophin partners with other research facilities to test its replacement therapy compounds to be used in the treatment of PKAN. The company markets its products through its authorized distributors. Retrophin is headquartered in San Diego, California, the US.
Retrophin Inc. (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Retrophin Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Retrophin Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Retrophin Inc., Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13
Venture Financing 14
Perlstein Lab Raises USD2 Million in Seed Financing 14
Retrophin Raises US$4 Million In Series A Financing 15
Partnerships 16
Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 16
Retrophin Enters Into Research Agreement With St. Jude Children's Research Hospital 17
Licensing Agreements 18
Retrophin Enters into Licensing Agreement with Mission Pharmacal for Thiola 18
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 19
Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 21
Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 22
Equity Offering 24
Retrophin Raises USD149.4 Million in Public Offering of Shares 24
Retrophin Raises USD40 Million in Public Offering of Shares 26
Retrophin Completes Private Placement Of Shares For US$25 Million 28
Retrophin Announces Private Placement Of Common Stock For US$10 Million 30
Debt Offering 31
Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 31
Asset Transactions 32
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 32
Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 33
Acquisition 35
Retrophin to Acquire Clinuvel Pharma 35
Retrophin Completes Acquisition Of Manchester Pharma For US$62.5 Million 37
Retrophin Terminates Acquisition Of Transcept Pharma For US$75 Million 39
Retrophin To Acquire Kyalin Biosciences, Autism Therapies Developer 41
Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 42
Retrophin Inc. - Key Competitors 43
Key Employees 44
Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List of Tables
Retrophin Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Retrophin Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Retrophin Inc., Deals By Therapy Area, 2010 to YTD 2016 9
Retrophin Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13
Perlstein Lab Raises USD2 Million in Seed Financing 14
Retrophin Raises US$4 Million In Series A Financing 15
Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 16
Retrophin Enters Into Research Agreement With St. Jude Children's Research Hospital 17
Retrophin Enters into Licensing Agreement with Mission Pharmacal for Thiola 18
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 19
Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 21
Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 22
Retrophin Raises USD149.4 Million in Public Offering of Shares 24
Retrophin Raises USD40 Million in Public Offering of Shares 26
Retrophin Completes Private Placement Of Shares For US$25 Million 28
Retrophin Announces Private Placement Of Common Stock For US$10 Million 30
Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 31
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 32
Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 33
Retrophin to Acquire Clinuvel Pharma 35
Retrophin Completes Acquisition Of Manchester Pharma For US$62.5 Million 37
Retrophin Terminates Acquisition Of Transcept Pharma For US$75 Million 39
Retrophin To Acquire Kyalin Biosciences, Autism Therapies Developer 41
Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 42
Retrophin Inc., Key Competitors 43
Retrophin Inc., Key Employees 44
Retrophin Inc., Other Locations 45
Retrophin Inc., Subsidiaries 45
List of Figures
Retrophin Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Retrophin Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Retrophin Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
